参考文献/References:
[1] Brigden W. Uncommon myocardial diseases:the non-coronary cardiomyopathies[J]. Lancet,1957,273(7008):1243-1249.
[2] Cronin EM,Bogun FM,Maury P,et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias[J]. J Interv Card Electrophysiol,2020,59(1):145-298.
[3] Kanagaratnam A,Virk SA,Pham T,et al. Catheter ablation for ventricular tachycardia in ischaemic versus non-ischaemic cardiomyopathy:a systematic review and meta-analysis[J]. Heart Lung Circ,2022,31(8):1064-1074.
[4] Bhaskaran A,Tung R,Stevenson WG,et al. Catheter ablation of VT in non-ischaemic cardiomyopathies:endocardial,epicardial and intramural approaches[J]. Heart Lung Circ,2019,28(1):84-101.
[5] Liuba I,Marchlinski FE. The substrate and ablation of ventricular tachycardia in patients with nonischemic cardiomyopathy[J]. Circ J,2013,77(8):1957-1966.
[6] Kotake Y,Nalliah CJ,Campbell T,et al. Comparison of the arrhythmogenic substrate for ventricular tachycardia in patients with ischemic vs non-ischemic cardiomyopathy-insights from high-density,multi-electrode catheter mapping[J]. J Interv Card Electrophysiol,2023,66(1):5-14.
[7] Chakarov I,Mueller J,Ene E,et al. Long-term outcomes after catheter ablation of ventricular tachycardia in dilated vs. ischemic cardiomyopathy[J]. J Clin Med,2022,11(14):4000.
[8] Muser D,Santangeli P,Castro SA,et al. Long-term outcome after catheter ablation of ventricular tachycardia in patients with nonischemic dilated cardiomyopathy[J]. Circ Arrhythm Electrophysiol,2016,9(10):e004328.
[9] Porcu M,Corda M,Pasqualucci D,et al. A very long-term observation of a family with dilated cardiomyopathy and overlapping phenotype from lamin A/C mutation[J]. J Cardiovasc Med (Hagerstown),2021,22(1):53-58.
[10] Kumar S,Androulakis AF,Sellal JM,et al. Multicenter experience with catheter ablation for ventricular tachycardia in lamin A/C cardiomyopathy[J]. Circ Arrhythm Electrophysiol,2016,9(8):e004357.
[11] Zeppenfeld K,Tfelt-Hansen J,de Riva M,et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death[J]. Eur Heart J,2022,43(40):3997-4126.
[12] Santangeli P,Zado ES,Supple GE,et al. Long-term outcome with catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy[J]. Circ Arrhythm Electrophysiol,2015,8(6):1413-1421.
[13] Mathew S,Saguner AM,Schenker N,et al. Catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia:a sequential approach[J]. J Am Heart Assoc,2019,8(5):e010365.
[14] Romero J,Patel K,Briceno D,et al. Endo-epicardial ablation vs endocardial ablation for the management of ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy:A systematic review and meta-analysis[J]. J Cardiovasc Electrophysiol,2020,31(8):2022-2031.
[15] Liang E,Wu L,Fan S,et al. Catheter ablation of arrhythmogenic right ventricular cardiomyopathy ventricular tachycardia:18-year experience in 284 patients[J]. Europace,2020,22(5):806-812.
[16] Dukkipati SR,d’Avila A,Soejima K,et al. Long-term outcomes of combined epicardial and endocardial ablation of monomorphic ventricular tachycardia related to hypertrophic cardiomyopathy[J]. Circ Arrhythm Electrophysiol,2011,4(2):185-194.
[17] Maron MS,Finley JJ,Bos JM,et al. Prevalence,clinical significance,and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy[J]. Circulation,2008,118(15):1541-1549.
[18] Igarashi M,Nogami A,Kurosaki K,et al. Radiofrequency catheter ablation of?ventricular tachycardia in patients with hypertrophic cardiomyopathy and?apical aneurysm[J]. JACC Clin Electrophysiol,2018,4(3):339-350.
[19] Naeemah QJ,Komatsu Y,Nogami A,et al. Catheter ablation of ventricular tachycardia in dilated-phase hypertrophic cardiomyopathy:Substrate characterization and ablation outcome[J]. Pacing Clin Electrophysiol,2022,45(6):773-785.
[20] Tung R,Xue Y,Chen M,et al. First-line catheter ablation of monomorphic ventricular tachycardia in cardiomyopathy concurrent with defibrillator implantation:the PAUSE-SCD randomized trial[J]. Circulation,2022,145(25):1839-1849.
[21] Della Bella P,Baratto F,Vergara P,et al. Does timing of ventricular tachycardia ablation affect prognosis in patients with an implantable cardioverter defibrillator?Results from the multicenter randomized PARTITA triall[J]. Circulation,2022,145(25):1829-1838.
[22] Ravi V,Poudyal A,Khanal S,et al. A systematic review and meta-analysis comparing radiofrequency catheter ablation with medical therapy for ventricular tachycardia in patients with ischemic and non-ischemic cardiomyopathies[J]. J Interv Card Electrophysiol,2023,66(1):161-175.
[23] Ding WY,Pearman CM,Bonnett L,et al. Complication rates following ventricular tachycardia ablation in ischaemic and non-ischaemic cardiomyopathies:a systematic review[J]. J Interv Card Electrophysiol,2022,63(1):59-67.
[24] Sciria CT,Kogan EV,Ip JE,et al. Trends and outcomes of catheter ablation of ventricular tachycardia in patients with ischemic and nonischemic cardiomyopathy[J]. Circ Arrhythm Electrophysiol,2022,15(4):e010742.
[25] Silberbauer J,Oloriz T,Maccabelli G,et al. Noninducibility and late potential abolition:a novel combined prognostic procedural end point for catheter ablation of postinfarction ventricular tachycardia[J]. Circ Arrhythm Electrophysiol,2014,7(3):424-435.
[26] Okubo K,Gigli L,Trevisi N,et al. Long-term outcome after ventricular tachycardia ablation in nonischemic cardiomyopathy:late potential abolition and VT noninducibility[J]. Circ Arrhythm Electrophysiol,2020,13(8):e008307.
相似文献/References:
[1]李才垚 王洪涛 秦兴华 刘鹏 郑强荪.心肌梗死后室性心动过速导管消融适应证在指南共识中的演变[J].心血管病学进展,2021,(5):421.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.009]
LI Caiyao,WANG Hongtao,QIN Xinghua,et al.Evolution of Indications for Ablation of Ventricular Tachycardia after Myocardial Infarction in Guidelines and Consensus[J].Advances in Cardiovascular Diseases,2021,(5):421.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.009]
[2]王思博 王连生.心肌梗死后室性心律失常的治疗进展[J].心血管病学进展,2021,(6):481.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.001]
WANG SiboWANG Liansheng.Treatment of Ventricular Arrhythmias after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2021,(5):481.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.001]
[3]王芯梦 崔凯军.心脏磁共振成像在室性心动过速消融治疗中的应用进展[J].心血管病学进展,2024,(1):48.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.013]
WANG Xinmeng,CUI Kaijun.Cardiac Magnetic Resonance Applied in Ablation of Ventricular Tachycardia[J].Advances in Cardiovascular Diseases,2024,(5):48.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.013]
[4]曹奕辉 李剑 周鹏.室性心动过速导管消融术后血栓栓塞预防治疗的研究进展[J].心血管病学进展,2024,(8):673.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.001]
CAO Yihui,LI Jian,ZHOU Peng.Recent Advances in Thromboembolism Prophylaxis after?atheter Ablation of Ventricular Tachycardia[J].Advances in Cardiovascular Diseases,2024,(5):673.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.001]